Transurethral radiotherapy for benign prostatic hypertrophy-related XXXX . Dosimetry, ethics, and preliminary results.

@entity1 @entity137 @entity263 @entity5 @entity105 @entity11044
The aim of this study is to present our preliminary experience in treating BPH-related urine retention, resistant to other medical treatment, with transurethral brachytherapy. We also deal with dosimetric analysis so as to eliminate ethical concerns about the exposure of @entity1 not suffering from @entity5 to a certain level of body irradiation. @entity1 suffering from BPH-related @entity11044 were treated with two transurethral applications (three weeks apart) of Cs137 MDR, which delivered a total of 16 Gy, at 0.5 cm from the urethral walls (dose rate 5-7 Gy/h). The application was done under ultrasonographic observation. Dosimetric calculation of the radiation exposure of the @entity1 body during transurethral radiotherapy (TURT) was performed for @entity1 suffering from @entity263 and treated with external beam radiotherapy and a boost dose through transurethral brachytherapy. For this purpose we used TLDs on skin surface and dosimetric analysis of X-ray films. Five @entity1 treated for @entity11044 presented no sign of acute @entity137 . All of them were weaned of their indwelling catheter immediately after the end of the first application. Obstruction did not recur within 12-18 months of follow-up. The dose delivered outside the prostate ranges from 1-7 cG, depending upon location. Proximal rectal and bladder walls received 1-2 Gy, a dose that is far from inducing acute or late @entity137 . The estimated risk for @entity105 is negligible, and the expected benefit for the quality of life transcends the risks. No ethical concern is justified for testing transurethral radiotherapy for BPH-related @entity11044 . TURT seems to be effective and provides durable results. Further investigation is required.
